Literature DB >> 6492045

Is there a role for radioimmunolocalization in diagnosis of intracranial malignancies?: discussion paper.

J T Kemshead, D H Jones, A Goldman, R B Richardson, H B Coakham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6492045      PMCID： PMC1440276          DOI： 10.1177/014107688407701010

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  31 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function.

Authors:  N A Vick; D D Bigner
Journal:  J Neurol Sci       Date:  1972-09       Impact factor: 3.181

Review 3.  Immunological considerations and the malignant glioma problem.

Authors:  M S Mahaley
Journal:  Clin Neurosurg       Date:  1968

4.  An acidic protein isolated from fibrous astrocytes.

Authors:  L F Eng; J J Vanderhaeghen; A Bignami; B Gerstl
Journal:  Brain Res       Date:  1971-05-07       Impact factor: 3.252

5.  Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.

Authors:  P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1981-04       Impact factor: 5.532

6.  Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication.

Authors:  R H Begent; F Searle; G Stanway; R F Jewkes; B E Jones; P Vernon; K D Bagshawe
Journal:  J R Soc Med       Date:  1980-09       Impact factor: 5.344

7.  Human glioma-associated antigens detected by monoclonal antibodies.

Authors:  J F Schnegg; A C Diserens; S Carrel; R S Accolla; N de Tribolet
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

8.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

9.  Radionuclide imaging of primary renal-cell carcinoma by I-131-labeled antitumor antibody.

Authors:  P Belitsky; T Ghose; J Aquino; S T Norvell; A H Blair
Journal:  J Nucl Med       Date:  1978-04       Impact factor: 10.057

10.  A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.

Authors:  J R Johnson; C H Ford; C E Newman; C S Woodhouse; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640
View more
  4 in total

1.  Radioimmunolocalization of human brain tumours: biodistribution of radiolabelled monoclonal antibody UJ13A.

Authors:  R B Richardson; A G Davies; S P Bourne; G E Staddon; D H Jones; J T Kemshead; H B Coakham
Journal:  Eur J Nucl Med       Date:  1986

2.  Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Authors:  D D Bigner; M Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; S H Bigner; X G Zhao; C J Wikstrand; C N Pegram
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Immunohistological diagnosis of central nervous system tumours using a monoclonal antibody panel.

Authors:  H B Coakham; J A Garson; P M Allan; E I Harper; B Brownell; J T Kemshead; E B Lane
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

4.  Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.

Authors:  V Papanastassiou; B L Pizer; H B Coakham; J Bullimore; T Zananiri; J T Kemshead
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.